Pharmacist-led education for adults with chronic obstructive pulmonary disease
Tests pharmacist-led teaching on taking medicines in adults with chronic obstructive pulmonary disease.
Plain-language title generated from the registry record
Registry title: ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among Chronic Obstructive Pulmonary Disease Patients
Key facts
- Where
- Buraidah, Saudi ArabiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07815353, who can take part
Where in Saudi Arabia
- Bander S AlshammeriBuraidah, Saudi ArabiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rabia Hussain
- Trial code
- NCT07815353
- Record updated
- 25 September 2026
- Original description
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia. This study will use a quantitative, quasi-experimental pretest-posttest control-group design. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will receive standard care without additional education. Baseline assessments will include medication adherence using the Morisky Medication Adherence Scale-8 (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.Read full original descriptionShow less
Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention on Medication Adherence, Quality of Life, and Direct Costs in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study
Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia. This study will use a quantitative, quasi-experimental pretest-posttest control-group design. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will receive standard care without additional education. Baseline assessments will include medication adherence using the Morisky Medication Adherence Scale-8 (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.
Inclusion: Participants must:; Be adults aged 18-65 years; Be diagnosed with chronic obstructive pulmonary disease (COPD) stages I-III according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; Have visited or been admitted for a COPD exacerbation and are receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia; Be Arabic-speaking and capable of understanding study instructions; Be willing and able to provide written informed consent.
Exclusion: Are immunocompromised or receiving immunosuppressive treatment; Have another significant pulmonary disease, including: Asthma, bronchiectasis, pneumonia, or cystic fibrosis; Have a serious systemic illness, severe comorbidity, or central organ dysfunction, including: Hepatic dysfunction, renal dysfunction, psychiatric impairment or sensory impairment; Have psychological, sensory, or cognitive impairment that prevents meaningful participation in the study; Participants will be excluded if they:; Are diagnosed with COPD stage IV.